Tech Company Financing Transactions
Adaptive Phage Therapeutics Funding Round
Alexandria Venture Investments participated in a $7 million funding round for Adaptive Phage Therapeutics. The round was announced on 10/8/2019.
Transaction Overview
Company Name
Announced On
10/8/2019
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds will be deployed to support multi-center phase 2 clinical studies for its PhageBank therapy for antibiotic resistant bacterial infections.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
708 Quince Orchard Rd. 205
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Website
Email Address
Overview
Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Merril
Chief Medical Officer
Michael Brownstein
Chief Operating Officer
Subhendu Basu
Chief Scientific Officer
Carl Merril
Vice President
Robert Hopkins
VP - Bus. Development
Michael King
VP - Finance
Michael Orndorff
VP - Manufacturing
Joseph Fackler
VP - Product Management
Robert Cohen
VP - Regulatory Affairs
Amy Fix
Browse more venture capital transactions:
Prev: 10/8/2019: Viola venture capital transaction
Next: 10/8/2019: Evrnu venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs